EA201500393A1 - Ингибиторы тирозинкиназы брутона - Google Patents

Ингибиторы тирозинкиназы брутона

Info

Publication number
EA201500393A1
EA201500393A1 EA201500393A EA201500393A EA201500393A1 EA 201500393 A1 EA201500393 A1 EA 201500393A1 EA 201500393 A EA201500393 A EA 201500393A EA 201500393 A EA201500393 A EA 201500393A EA 201500393 A1 EA201500393 A1 EA 201500393A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conditions
compounds
bluton
inhibitors
diseases
Prior art date
Application number
EA201500393A
Other languages
English (en)
Inventor
Джон Роберт Шпрингер
Балекудру Девадас
Денни Джеймс Гарланд
Маргарет Ланахан Грэпперхаус
Сиунгил Хан
Сюзан Лэндис Хокерман
Роберт Оуен Хаджис
Еддин Сэиа
Марк Эвард Шунте
Шаун Рай Селнесс
Даниэль Патрик Вокер
Джао-Куи Ван
Ли Ксинг
Кристоф Вольфганг Запф
Мишель Энн Шмидт
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201500393(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA201500393A1 publication Critical patent/EA201500393A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Данный документ описывает соединения, образующие ковалентные связи с тирозинкиназой Брутона (ТКБ). Описаны способы получение таких соединений. Также описаны фармацевтические композиции, содержащие такие соединения. Описаны способы использования ингибиторов ТКБ, самих по себе или в комбинации с другими терапевтическими агентами, для лечения аутоиммунных заболеваний или состояний, гетероиммунных заболеваний или состояний, рака, включая лимфому, и воспалительных заболеваний или состояний.
EA201500393A 2012-11-02 2013-11-01 Ингибиторы тирозинкиназы брутона EA201500393A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04
PCT/IB2013/059846 WO2014068527A1 (en) 2012-11-02 2013-11-01 Bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201500393A1 true EA201500393A1 (ru) 2016-05-31

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500393A EA201500393A1 (ru) 2012-11-02 2013-11-01 Ингибиторы тирозинкиназы брутона

Country Status (27)

Country Link
US (4) US20150291554A1 (ru)
EP (1) EP2914586B1 (ru)
JP (1) JP6178861B2 (ru)
KR (1) KR101668574B1 (ru)
CN (1) CN105008344B (ru)
AP (1) AP2015008381A0 (ru)
AU (1) AU2013340345B2 (ru)
BR (1) BR112015009624A2 (ru)
CA (1) CA2888960C (ru)
CL (1) CL2015001168A1 (ru)
CO (1) CO7350624A2 (ru)
CR (1) CR20150228A (ru)
DO (1) DOP2015000100A (ru)
EA (1) EA201500393A1 (ru)
ES (1) ES2625944T3 (ru)
GE (1) GEP201606597B (ru)
HK (1) HK1211293A1 (ru)
IL (1) IL238571A0 (ru)
MD (1) MD20150035A2 (ru)
MX (1) MX2015005422A (ru)
NI (1) NI201500059A (ru)
PE (1) PE20151070A1 (ru)
PH (1) PH12015500940A1 (ru)
SG (1) SG11201502893WA (ru)
TN (1) TN2015000168A1 (ru)
TW (1) TWI518080B (ru)
WO (1) WO2014068527A1 (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001802A (es) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Compounds of pyrazolopyrimidine, as kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2970163B1 (en) 2013-03-14 2018-02-28 Boehringer Ingelheim International GmbH 5-thiazolecarboxamide dervatives and their use as btk inhibitors
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
SG10201809696UA (en) * 2013-03-15 2018-11-29 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
EP2970300B1 (en) 2013-03-15 2018-05-16 Boehringer Ingelheim International GmbH Heteroaromatic compounds as btk inhibitors
EP4234036A3 (en) * 2013-08-19 2023-11-01 TARIS Biomedical LLC Multi-unit drug delivery devices
MX2016004030A (es) * 2013-09-30 2016-10-26 Beijing Synercare Pharma Tech Co Ltd Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
CA2939186C (en) 2014-02-21 2023-03-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
TW201607930A (zh) * 2014-07-18 2016-03-01 百濟神州有限公司 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
WO2016100914A1 (en) 2014-12-18 2016-06-23 Gourlay Steven Treatment of pemphigus
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN108431007B (zh) 2015-09-16 2022-06-07 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
FI3377484T3 (fi) * 2015-11-17 2023-11-30 Merck Patent Gmbh Menetelmiä multippeliskleroosin hoitoon käyttämällä pyrimidiini- ja pyridiiniyhdisteitä, joilla on BTK inhiboiva vaikutus
LT3390390T (lt) 2015-12-16 2021-11-25 Boehringer Ingelheim International Gmbh Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
SG10202012498TA (en) * 2015-12-16 2021-01-28 Loxo Oncology Inc Compounds useful as kinase inhibitors
JP6916185B2 (ja) 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのイソキノロン類
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
EP3459940B8 (en) * 2016-05-16 2022-08-24 Evopoint Biosciences Co., Ltd. 5-aminopyrazole carboxamide derivative as btk inhibitor and preparation method and pharmaceutical composition thereof
CA3028169A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
IL272838B2 (en) 2017-10-06 2023-09-01 Forma Therapeutics Inc Peptidase-specific ubiquitin inhibition 30
AU2018364183B2 (en) * 2017-11-10 2020-10-15 Sinomab Bioscience Limited Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor
CN111225912B (zh) * 2017-11-10 2020-11-10 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
CN111212644B (zh) * 2017-11-10 2021-01-15 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
AU2019356011A1 (en) 2018-10-05 2021-04-01 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020234379A1 (en) * 2019-05-21 2020-11-26 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115611810A (zh) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
TW202342444A (zh) * 2022-02-04 2023-11-01 美商理通製藥公司 特定化學實體、組合物及方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
JP2006515828A (ja) * 2001-09-27 2006-06-08 スミスクライン・ビーチャム・コーポレイション 化学化合物
CA2648923A1 (en) 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
HUE028086T2 (en) 2006-09-22 2016-11-28 Pharmacyclics Llc Bruton tyrosine kinase inhibitors
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AU2008276521B2 (en) * 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
WO2010009342A2 (en) * 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8541575B2 (en) 2008-07-24 2013-09-24 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
US8685969B2 (en) * 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
MX2015001802A (es) * 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10105632B2 (en) 2014-04-09 2018-10-23 Donaldson Company, Inc. Self-supporting folded sheet material, filter elements, and methods
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
CN105008344A (zh) 2015-10-28
PH12015500940A1 (en) 2015-06-29
TN2015000168A1 (fr) 2016-10-03
SG11201502893WA (en) 2015-05-28
US20210002251A1 (en) 2021-01-07
HK1211293A1 (en) 2016-05-20
WO2014068527A1 (en) 2014-05-08
US20150291554A1 (en) 2015-10-15
CO7350624A2 (es) 2015-08-10
EP2914586B1 (en) 2017-04-05
JP6178861B2 (ja) 2017-08-09
TWI518080B (zh) 2016-01-21
DOP2015000100A (es) 2015-12-31
US10266513B2 (en) 2019-04-23
AU2013340345A1 (en) 2015-04-30
CA2888960A1 (en) 2014-05-08
TW201431851A (zh) 2014-08-16
PE20151070A1 (es) 2015-08-01
ES2625944T3 (es) 2017-07-21
CN105008344B (zh) 2017-07-25
US20170283393A1 (en) 2017-10-05
CL2015001168A1 (es) 2015-07-10
MD20150035A2 (ru) 2015-10-31
BR112015009624A2 (pt) 2017-11-14
KR101668574B1 (ko) 2016-10-24
US10815213B2 (en) 2020-10-27
GEP201606597B (en) 2017-01-10
US20190202798A1 (en) 2019-07-04
EP2914586A1 (en) 2015-09-09
CR20150228A (es) 2015-09-14
KR20150075114A (ko) 2015-07-02
JP2015535277A (ja) 2015-12-10
NI201500059A (es) 2015-06-05
CA2888960C (en) 2017-08-15
IL238571A0 (en) 2015-06-30
AP2015008381A0 (en) 2015-04-30
MX2015005422A (es) 2015-08-05
AU2013340345B2 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
NZ707086A (en) Anti-cd40 antibodies and methods of use
IN2014KN02601A (ru)
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2012005507A (es) Antagonistas de espiro-oxindol de mdm2.
BR112013033807A2 (pt) formulações pirroloquinolinil-pirrolidin-2,5-diona e métodos para sua preparação
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
EA202092370A1 (ru) Новые модуляторы киназ